Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses (RESPIRE)

27. juli 2026 oppdatert av: SynAct Pharma Aps

A Randomized, Double-blind, Multicentre, Placebo-controlled, Proof-of-concept Clinical Trial Evaluating the Safety and Efficacy of the Biased Melanocortin Agonist AP1189 Versus Placebo as an add-on to Standard of Care (SOC) in Participants With RESPIRatory Insufficiency Expected to be Caused by Infection With Respiratory Viruses, Including Influenza, Respiratory Syncytial Virus, and Coronavirus

A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected to be caused by respiratory viral infection.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The purpose of the trial is to evaluate the efficacy and safety 14 days daily treatment of oral AP1189 at a dose or 100 mg as an add-on to SOC treatment.

The aim is to have 96 participants randomized and completing the study. They will be randomized in a 1:1 ratio to one of the following two groups:

  • Group A (48 participants): AP1189 tablets 100 mg, once daily for 14 days as an add-on to SOC
  • Group B (48 participants): placebo tablets once daily for 14 days as an add-on to SOC.

Studietype

Intervensjonell

Registrering (Antatt)

96

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Bosnia og Herzegovina
    • Herzegovina-Neretva Canton
      • Mostar, Herzegovina-Neretva Canton, Bosnia og Herzegovina, 88000
        • Rekruttering
        • University Clinical Hospital Mostar, Clinic for Infectious Diseases
        • Ta kontakt med:
    • Republika Srpska
      • Banja Luka, Republika Srpska, Bosnia og Herzegovina, 78000
        • Rekruttering
        • University Clinical Center Republic of Srpska, Clinic for Infectious Diseases
        • Ta kontakt med:
    • Sarajevo Canton
      • Sarajevo, Sarajevo Canton, Bosnia og Herzegovina, 71000
        • Rekruttering
        • University Clinical Centre Sarajevo, Clinic for Infectious Diseases
        • Ta kontakt med:
  • Montenegro
    • Podgorica Municipality
      • Podgorica, Podgorica Municipality, Montenegro, 81000
        • Rekruttering
        • Clinical Center of Montenegro, Clinic for Infectious Diseases
        • Ta kontakt med:
  • New Zealand
      • Auckland, New Zealand, 1023
        • Rekruttering
        • Te Toka Tumai Auckland, Auckland City Hospital
        • Ta kontakt med:
          • Tom Hills, Dr.
      • Auckland, New Zealand, 2025
        • Rekruttering
        • Aotearoa Clinical Trial Trust, Esme Green Building, Middlemore Hospital
        • Ta kontakt med:
          • Michael Borrie, Dr.
      • Christchurch, New Zealand, 8011
        • Har ikke rekruttert ennå
        • Christchurch Hospital, 2 Riccarton Avenue,
        • Ta kontakt med:
          • Seton Henderson, Dr.
      • Wellington, New Zealand, 6021
        • Rekruttering
        • MRINZ, 7 CSB Building, Wellington Hospital
        • Ta kontakt med:
          • Max Bloomfield, Dr.
  • Serbia
      • Belgrade, Serbia, 11000
        • Rekruttering
        • University Clinical Centre of Serbia, Clinic for Infectious Diseases
        • Ta kontakt med:
    • Nišava District
      • Niš, Nišava District, Serbia, 18000
        • Rekruttering
        • University Clinical Centre Nis, Clinic for Infectious Diseases
        • Ta kontakt med:
    • Zlatibor District
      • Užice, Zlatibor District, Serbia, 31000
        • Rekruttering
        • Health Center Uzice, General Hospital Uzice
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Written informed consent has been obtained prior to initiating any study-specific procedures
  • Expected respiratory viral infection, and positive for either SARS-COV-2, Influenza A or B, or RSV as confirmed by a bedside LAF test, qualitative PCR, or quantitative PCR (Q-PCR).
  • Hospitalized with respiratory insufficiency expected to be caused by respiratory viral infection defined by SpO2 ≤ 93 % on ambient air or supplementary oxygen supply via nasal catheter or facial mask (WHO Clinical Progression Scale score 5 or 6). Or in participants with hypercapnic respiratory failure (usually due to COPD) the SpO2 threshold is SpO2 ≤ 85 %.
  • Duration of disease from first symptom< 15 days before enrolment
  • Females of childbearing potential using reliable means of contraception or are post-menopausal or are surgically sterilized
  • Females of childbearing potential with a negative pregnancy test at screening and baseline
  • As the morbidity and mortality of respiratory infections are many fold increased in vulnerable participants, vulnerable participants are not excluded but included as subgroups.
  • Screened within 24 hours of hospital admission to the hospital, or within 24 hours of receiving a patient, if the patient is transferred from another hospital or another hospital department due to respiratory distress

Exclusion Criteria:

  • In the investigator's opinion, progression to death is imminent and inevitable irrespective of the provision of treatment
  • Already meeting any component of the primary composite endpoint at screening, defined as the presence of any of the following: invasive mechanical ventilation, ECMO, cardiovascular organ support (balloon pump or inotropes/vasopressors), or renal failure (Cockcroft-Gault estimated creatinine clearance <15 ml/min, haemofiltration or dialysis). Note: participants qualifying under inclusion criterion 8b (pre-existing renal insufficiency or dialysis) are excluded only if they meet any of the other criteria (invasive mechanical ventilation, ECMO, or cardiovascular organ support). Participants who are physically located in an ICU or HDU but do not meet the above physiological criteria are not excluded on that basis alone.
  • Participating in other drug clinical trials
  • Any condition that in the view of the screening physician would suggest that the participant is unable to comply with study protocol and procedures
  • Participants who have initiated treatment within 3 months prior to screening with immunosuppressive or immunomodulatory treatments for chronic autoimmune diseases. Administration of steroids or other immunosuppressive medicines implemented as standard-of-care for the treatment of the respiratory viral infection is acceptable. Asthma/COPD participants are allowed to use their habitual inhalation spray containing adrenocortical hormone.
  • Pregnant women or nursing (breastfeeding) mothers

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: AP1189, 100 mg
AP1189 tablet for oral use
Legemiddel: AP1189, 100 mg
14 days of daily treatment of oral AP1189 100 mg as add-on to Standard of Care treatment
Eksperimentell: AP1189 matching placebo
AP1189 tablet for oral use
Legemiddel: Placebo
14 days of daily treatment of AP1189 matching placebo as add-on to Standard of Care treatment

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of participants meeting the composite endpoint, consisting of either death, invasive mechanical ventilation, ECMO, cardiovascular organ support, new occurrences of renal failure, hemofiltration or dialysis from baseline to day 28
Tidsramme: 28 days
28 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

SynAct Pharma Aps

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mai 2026

Primær fullføring (Antatt)

1. august 2027

Studiet fullført (Antatt)

1. august 2027

Datoer for studieregistrering

Først innsendt

2. juni 2026

Først innsendt som oppfylte QC-kriteriene

2. juni 2026

Først lagt ut (Faktiske)

8. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • SynAct-CS009

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere